Location:

Local - Pennsylvania

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Hip implants, orthopaedics, ARMD, hip implants

Implant-Specific Blood Metal Ion Levels Can Effectively Identify Patients at Low Risk of Adverse Reactions after 'Metal on Metal' Hip Replacement

Patients with "metal on metal" (MoM) artificial hips are at risk of complications caused by adverse reactions to metal debris (ARMD). A study in the September 20, 2017 issue of The Journal of Bone & Joint Surgery confirms that blood metal .

Business

Channels:

Cancer, Hospital, Healthcare

UPMC Invests in Private Rome Hospital, Plans Expansion of Specialized Services

UPMC has taken a 50 percent stake in Salvator Mundi International Hospital and will expand specialized services.

Medicine

Channels:

Virology, business economics, pharmaceutial science, Medicine & Health, Vaccines, Public Health, Immunology, Infectious Disease

Flu Vaccine Used in Elderly May Benefit Middle-Aged Adults with Chronic Conditions

Expanding the high-dose influenza vaccine recommendation to include middle-aged adults with chronic health conditions may make economic sense and save lives. The findings may justify for clinical trials of the high-dose and new recombinant trivalent influenza vaccines in 50- to 64-year-old adults with chronic illnesses, such as heart or lung disease, diabetes, or cancer, to determine if they do provide considerably better protection than the currently recommended standard dose quadrivalent vaccine.

Medicine

Channels:

Radiation, Cancer, Radiation Oncolgy

Penn First in World to Treat Patient with New Radiation Technology

Halcyon1.jpg

Doctors at Penn Medicine have become the first in the world to treat a patient with a new treatment platform designed to streamline the way therapeutic radiation is delivered to cancer patients.

Medicine

Science

Channels:

melanoma cells, dissemination

Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties

A study conducted at The Wistar Institute has led to the identification of a slowly proliferating and highly invasive melanoma cell subpopulation, characterized by production of a protein associated with invasive behavior.

Life

Social and Behavioral Sciences

Channels:

Sports, Sport, Sport Management, Gaming, Sports Betting, Supreme Court, Law, higher ediucation, Research

Temple University Expert Available to Discuss Supreme Court Case on New Jersey Sports Betting

Life

Law and Public Policy

Channels:

Business, Business School, Law, Public Policy, Immigration, Legal Studies, Temple University, Fox School of Business

Temple University Professor Available to Discuss Current Issues in Immigration

Medicine

Channels:

Mtor, mTOR inhibitors, Autophagy, PPT1

Penn Researchers Identify New Target, Develop New Drug for Cancer Therapies

PPT1Jpeg.jpg

Opening up a new pathway to fight cancer, researchers at the University of Pennsylvania have found a way to target an enzyme that is crucial to tumor growth while also blocking the mechanism that has made past attempts to target that enzyme resistant to treatment. Researchers were able to use this finding to develop a drug that successfully inhibits tumor growth of melanoma as well as pancreatic and colorectal cancer in mice.

Medicine

Channels:

Gluten, gluten allergy, Gluten Free, Celiac Disease

The Medical Minute: Going ‘Gluten-Free’ Not for Everyone

CeliacDiseaseNR.jpg

More and more often, we see “gluten-free” food options on store shelves and restaurant menus. But what does “gluten-free” mean and why have such products become so popular?

Science

Channels:

Melanoma, Resistance, cross-talk

Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells (“TABs”) in melanoma progression and resistance to targeted therapy.







Chat now!